Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by SCRI Development Innovations, LLC
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT01401959
First received: July 20, 2011
Last updated: October 13, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)